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Understanding pathogenesis at the molecular level is the ﬁrst step toward developing new therapeutic approaches. Here, we
review the molecular mechanisms of visual dysfunction in two common diseases, innate chorioretinal inﬂammation and diabetic
retinopathy, and the role of the ubiquitin-proteasome system (UPS) in both processes. In innate chorioretinal inﬂammation,
interleukin-6 family ligands induce STAT3 activation in photoreceptors, which causes UPS-mediated excessive degradation of the
visual substance, rhodopsin. In diabetic retinopathy, angiotensin II type 1 receptor (AT1R) signaling activates ERK in the inner
layers of the retina, causing UPS-mediated excessive degradation of the synaptic vesicle protein, synaptophysin. This latter eﬀect
may decrease synaptic activity, in turn adversely aﬀecting neuronal survival. Both mechanisms involve increased UPS activity and
the subsequent excessive degradation of a protein required for visual function. Finally, we review the therapeutic potential of
regulating the UPS to protect tissue function, citing examples from clinical applications in other medical ﬁelds.
1.Introduction
Recent progress in molecular biology has revealed the
molecular basis in the pathogenesis of various diseases.
Molecular targeting therapies have been developed, primar-
ily in the ﬁeld of vascular biology. One such therapy is
antivascular endothelial growth factor (anti-VEGF) therapy,
which is now widely used to treat age-related macular
degeneration (AMD) and cancer. Its role in treating AMD
is to regulate ocular vascular lesions and prevent secondary
damagetotheneuralretinalcells,whicharecriticalforvisual
function.
The ﬁrst research into VEGF was reported in the 1970s
[1], and in 2004 the FDA approved the ﬁrst anti-VEGF
drug for clinical use in human eyes [2]. Basic research on
neurotrophic regulation also began in the 1970s [3], but
clinical trials started only recently [4]. Molecular-targeting
therapies for retinal neuroprotection are on the horizon,
and further studies are needed to understand the molecular
mechanisms in retinal diseases and to explore new treatment
approaches.
In the treatment of retinal diseases, developing neuro-
protective therapies for neural retinal cells deserves special
emphasis;thesecellshaveaverylimitedregenerativecapacity
and are critical to vision. The neural retinal cells derive
fromthemonolayeroftheneuraltubeduringembryogenesis
and are part of the central nervous system. Damage to
these cells occurs in common diseases such as chorioretinal
inﬂammation and diabetic retinopathy, as well as in less-
common conditions, like retinitis pigmentosa, a hereditary
retinal degeneration with mutated genes in the retinal
cells. Severe chorioretinal inﬂammation acutely disturbs
visual function [5]. Diabetes chronically aﬀects it, even
in the absence of obvious microangiopathy [6–8]: patients
experience a gradual loss of visual function even when
diabetic neovascularization is well regulated by vitreous
surgery and/or anti-VEGF therapy. In AMD, local retinal
inﬂammation is involved in the process of vision loss;2 Journal of Ophthalmology
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Figure 1: Model of the gp130-STAT3-SOCS3 pathway. IL-6 family
ligands activate the gp130 receptor, which subsequently phospho-
rylates and activates STAT3 through JAK. Activated and dimerized
STAT3 translocates into the nucleus to promote the transcription of
various molecules, including SOCS3 and IL-6. SOCS3 inhibits JAK
and STAT3 activation. IL-6 is secreted and further activates STAT3.
association of inﬂammatory molecules is reported in both
early and late stage AMD [9]. Inﬂammatory cytokines can
play a role in most of these changes.
However, the investigation of the molecular mechanisms
of retinal neuropathogenesis is in its early stages. Here, we
describe the molecular mechanism of neurodegeneration
that we recently reported in animal models of innate
chorioretinal inﬂammation (endotoxin-induced uveitis) and
diabetic retinopathy, and compare our ﬁndings with studies
from other ﬁelds to obtain additional clues to the pathogen-
esis of retinal diseases.
2.Retinal NeuronalChanges inInnate
Chorioretinal Inﬂammation
Inﬂammatory cytokines such as interleukin-6 (IL-6) are
closely connected to retinal diseases. Clinical reports show
that IL-6 in the vitreous ﬂuid increases not only in uveitis
[10] but also in diabetic retinopathy [11, 12], retinal vein
occlusion [13], and retinal detachment [14].
2.1. IL-6 Family Ligands and STAT3/SOCS3 Pathway in
the Retina. Research with experimental animals has shown
that diﬀusible factors, IL-6 and other proteins in the IL-6
family, such as leukemia inhibitory factor (LIF) and ciliary
neurotrophic factor (CNTF), are expressed in the retina.
Both IL-6 [15]a n dL I F[ 16]a r ef o u n di nM ¨ uller glial
cells, and CNTF is found in the retinal ganglion cells and
astrocytes around the vessels [17]. These endogenous IL-6
family proteins are upregulated during inﬂammation and
function to promote pathogenesis of the vascular system
[18].
IL-6 family proteins use cytokine-speciﬁc receptors to
activate a transmembrane receptor, gp130 [19], which then
recruits Janus kinase (JAK) to activate transcription factor
signal transducer and activator of transcription 3 (STAT3).
STAT3 then regulates various molecules at the transcrip-
tional level, including suppressor of cytokine signaling 3
(SOCS3). SOCS3 acts as a negative feedback modulator of
STAT3 by inhibiting JAK and subsequent STAT3 activation
[20]( Figure 1). In the retina, SOCS3 is expressed in the
photoreceptor cells, M¨ uller glial cells, and retinal ganglion
cells, and it inhibits STAT3 activation in these cells [21, 22].
Since STAT3 activation induces further STAT3-activating
factors, such as the IL-6 family ligands [23], the balance
between STAT3 activation and SOCS3 level is one of the key
determinants of an inﬂammatory reaction [23, 24].
2.2. STAT3/SOCS3 Pathway in the Developing Retina. This
balance between STAT3 and SOCS3 also plays an important
role during the development of the retina; activated STAT3
inhibits the photoreceptor-speciﬁc transcription factorcrxat
the transcriptional level, which in turn inhibits downstream
photoreceptor-speciﬁc markers such as rhodopsin [25].
Retina-speciﬁc conditional knockout mice of SOCS3, α-Cre
SOCS3 ﬂox/ﬂox mice (SOCS3CKO), induce increase in the
endogenous STAT3 activation, and show delay in the initia-
tion of rhodopsin expression at the transcriptional level [22].
STAT3 is activated in the embryonic retina but is shut down
by SOCS3 which appears in the neonatal retina, thereby
allowing rod photoreceptor cell diﬀerentiation. Therefore,
the timing of rod photoreceptor cell diﬀerentiation is ﬁne-
tuned by the initiation of SOCS3 expression and downregu-
lation of STAT3 activation. Although STAT3 activation in the
SOCS3CKO retina is still upregulated in the adulthood, the
rhodopsin level in the SOCS3CKO mice is compensated for
by as-yet-unknown mechanisms and matches that of wild-
type mice.
2.3. STAT3/SOCS3 Pathway in the Adult Retina with Inﬂam-
mation. A murine model of accelerated innate immunity,
the endotoxin-induced uveitis model (EIU model), was used
to further analyze the role of the gp130-STAT3-SOCS3
loop in adult retinal inﬂammation. In this model, uveitis is
induced by administering lipopolysaccharide (LPS). Inﬂam-
matory cytokine, IL-6 is upregulated [18], leading to STAT3
activation [21, 26, 27] in the retina. This induction does
not cause retinal cellular apoptosis, but it does reduce visual
function [21, 26, 27]: rhodopsin protein levels decrease,
and the rod photoreceptor outer segments (OSs), where
rhodopsin is concentrated, are shortened. The scotopic
electroretinogram (ERG) a-wave amplitude, which repre-
sents rod photoreceptor cell function, also decreases. STAT3
activation correlates with the rhodopsin reduction in the
adultretina,asinthedevelopingretina.Surprisingly,though,Journal of Ophthalmology 3
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Figure 2: STAT3 activation and rhodopsin protein levels in the retina of EIU model generated in SOCS3CKO mice. Immunoblot analyses. In
the SOCS3CKO retina, phosphorylated and activated STAT3 are upregulated in the control condition, and more greatly increased in the EIU
model induced by LPS (a, c). Although the rhodopsin protein level in the adult SOCS3CKO retina is almost the same as wild-type retina
under control condition, its level was more severely reduced in the EIU model induced by LPS (b, d). WT: wild-type; KO, SOCS3CKO; LPS:
lipopolysaccharide; pSTAT3: phosphorylated STAT3; EIU: endotoxin-induced uveitis. This research was originally published in J Biol Chem.
Ozawa Y, et al. Roles of STAT3/SOCS3 Pathway in Regulating the Visual Function and Ubiquitin-Proteasome-dependent Degradation of
Rhodopsin during Retinal Inﬂammation. J Biol Chem. 2008; 283(36):24561–24570. the American Society for Biochemistry and Molecular
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neither rhodopsin mRNA nor its upstream regulator, crx,
decreases in the adult retina during inﬂammation. This
suggests that a diﬀerent mechanism is involved in rhodopsin
and crx regulation in the adult retina than in the developing
retina [22, 25].
The role of activated STAT3 in retinal dysfunction during
inﬂammation has been analyzed using SOCS3CKO mice
[21]. In these SOCS3-deﬁcient mice, STAT3 activation can
increase greatly in the retina (Figures 2(a) and 2(c)). Thus,
we have hypothesized that the mechanism of rhodopsin
reduction during inﬂammation might be enhanced in these
cells.
As expected, the EIU models generated in the adult
SOCS3CKO mice showed a relative depletion of rhodopsin
protein (Figures 2(b) and 2(d)), followed by OS shortening.
The subsequent rod photoreceptor cell dysfunction, as
measured by scotopic ERG, was prolonged. This model also
revealed that during inﬂammation, rhodopsin reduction is
not regulated at the transcriptional level, but by a post-
transcriptional inhibitory mechanism. The reduction in
rhodopsin protein levels is rapid and global, starting only
several hours from the onset of inﬂammation.
2.4. STAT3-Induced Rhodopsin Degradation through UPS.
Under stress conditions, massive protein degradation
through the ubiquitin-proteasome system (UPS) is known
to increase [28]. A genetically abnormal rhodopsin protein
that causes autosomal dominant retinitis pigmentosa, P23H,
interacts with the UPS and forms aggresomes when over-
expressed in a cell line [29, 30]. Aggresomes are inclusion
bodies of accumulated waste proteins, formed when cellular
degradation machinery is impaired or overwhelmed, and
they are a pathologic ﬁnding in neurodegenerative diseases.
In the case of P23H, the rhodopsin protein folds abnormally
and accumulates rather than following the normal process
of elimination from the cell. This ﬁnding hinted that
geneticallynormalrhodopsinproteinmightalsobedegraded
extensively following the excessive induction of the UPS by
inﬂammation. Moreover, ubiquitin is present in the rod OS4 Journal of Ophthalmology
<Innate inﬂammation>
IL-6 family ligands
gp130 receptor
STAT3 activation
UPS (via UBR1?)
Rhodopsin degradation
“Visual dysfunction”
Figure 3:Modelofthemolecularmechanisminretinalinﬂammation.
IL-6familyligandsinduceSTAT3activation,whichpromotesexces-
sive UPS-mediated rhodopsin protein degradation and subsequent
visual dysfunction.
under control conditions [31], thus it can rapidly degrade
rhodopsin as needed. This hypothesis has been clearly
veriﬁed in vivo and in vitro [21]. Elevated levels of ubiquitin-
conjugated rhodopsin are followed by rhodopsin depletion
in the SOCS3CKO EIU mouse model. The same process
occurs in wild-type mice, but it is more rapid and more
severe in the SOCS3CKO mice, in which STAT3 activation
is increased. Therefore, the activated STAT3 level correlates
with the ubiquitination and degradation of rhodopsin.
This has been conﬁrmed in vitro by using JAK inhibitor
to inhibit IL-6-induced STAT3 activation. It is illustrated
by the preservation of rhodopsin levels under IL-6-induced
STAT3 activation, when a STAT3-dependent ubiquitin E3
ligase, ubiquitin-protein ligase E3 component n-recognin
1 (UBR1), is inhibited through the small inhibitory RNA
(siRNA) system. UBR1 is expressed in the OSs. We propose
that it contributes to rhodopsin protein degradation during
inﬂammation, especially given that inﬂammatory cytokines,
including IL-6, LIF, and CNTF, induce the ubiquitin-
conjugation of rhodopsin protein and UBR1 expression in
the rod photoreceptor cells, resulting in excessive rhodopsin
degradation and disturbed visual functioning (Figure 3).
2.5. Other Molecules Related to STAT3 Activation during
Inﬂammation. This process lasts as long as STAT3 is acti-
vated. STAT3 can be activated not only through the gp130
receptor, but also through an inﬂammatory diﬀusible factor,
angiotensin II. An angiotensin II type 1 receptor blocker
(ARB) suppresses STAT3 activation [26] during inﬂam-
mation directly, or indirectly, inhibiting IL-6 production,
thereby preserving rhodopsin levels and visual function.
AngiotensinIIalsoinducesoxidativestress,whichcaninduce
the ubiquitination of speciﬁc proteins [32]. The antioxidant
lutein, which suppresses oxidative stress and the induction
of reactive oxygen species (ROS) during inﬂammation, also
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Figure 4: Impairment of visual function and the protective eﬀect of
ARB in diabetic mice. OPs in ERG from diabetic or nondiabetic
mice. Amplitude and implicit time of OPs are impaired in the dia-
betic mice, but these changes were avoided by administrating ARB
(Telmisartan). ERG: electroretinogram; Ops: oscillatory potentials;
ARB: Angiotensin II type 1 receptor blocker.
reduces STAT3 activation, thus preserving the rhodopsin
level and visual function during inﬂammation [27].
Therefore, the mechanism of visual dysfunction is, at
least in part, explained by the excessive degradation of the
essential protein during inﬂammation.
3.RetinalNeuronalChanges inDiabetes
In diabetic retinopathy, the main ﬁndings include microan-
giopathy [33, 34] and neurodegeneration [35, 36]. Visual
dysfunction begins before vascular abnormalities become
obvious [6–8], and inner retinal dysfunction is reﬂected
in changes in ERG oscillatory potentials (OPs) (Figure 4).
However, little is known about the molecular mechanism of
diabetes-related neuronal degeneration. Our recent analyses
using a streptozotocin- (STZ-) induced type 1 diabetes
model shed light on this critical issue [35, 36].
3.1. Angiotensin II and Its Type1 Receptor Signaling. Both
diabetes and hypertension are involved in metabolic syn-
drome, in which angiotensin II signaling plays an important
role. ARBs have been approved for treatment of not only
high blood pressure, but also diabetes-related renal failure
[37]. Angiotensin II is converted from angiotensinogen in
a stepwise fashion by enzymes, including renin, angiotensin
converting enzyme, and others. Angiotensin II can bind to
either the angiotensin II type 1 receptor (AT1R) or type 2
receptor (AT2R) on the cell surface, which in turn activates
several contextually-dependent intracellular signals. These
components of the rennin angiotensin system (RAS) are allJournal of Ophthalmology 5
present physiologically in the retina, and are upregulated in
pathological conditions, as we have shown in the murine
model retina of STZ-induced diabetes [35].
AT1R is coexpressed with the major synaptic vesicle
protein synaptophysin in the inner layers of the retina [26].
This is consistent with several previous reports showing the
synaptic expression of AT1R in the brain [38, 39]. Synap-
tophysin, a synapse marker, is reduced in the postmortem
brains of patients who had had neurodegenerative diseases
such as Parkinson’s disease and Alzheimer’s disease [40].
Given that the OPs in ERG originate from inner retinal
neurons bearing AT1R, these ERG changes may represent
angiotensin II-induced synaptophysin dysregulation and the
resulting damage to visual function.
We have veriﬁed this hypothesis by administering ARB
(either telmisartan or valsartan) to STZ-induced diabetic
mice [35]. ARBs protect the expression of synaptophysin
protein and OPs in the diabetic retina (Figure 4). Interest-
ingly, synaptophysin mRNA is not reduced in the diabetic
retina, indicating that the protein’s reduction is regulated
post-transcriptionally.
3.2.AT1R-MediatedSynaptophysinDegradationthroughUPS.
Post-transcriptional synaptophysin reduction caused by
angiotensin II exposure was reproduced in a rat neuronal
cell line, PC12 [35]. In this system, synaptophysin protein
degradationisinhibitedbytheproteasomeinhibitorMG132,
but not the lysosome inhibitor E64. AT1R and its down-
stream extracellular signal-related protein kinase (ERK)
activation induce synaptophysin degradation, and AT1R
increases the ubiquitin-conjugated synaptophysin protein
levels. Angiotensin II signaling activates ERK in the diabetic
retina in vivo, suggesting that the AT1R-ERK pathway is
responsible for diabetes-induced pathogenic protein degra-
dation through the UPS.
Synaptophysin protein may be degraded by the mam-
malian homolog of Drosophila s e v e ni na b s e n t i a( s i n a ) ,
an E3-ligase selective for synaptophysin named seven in
absentiahomologue(Siah).SinceDrosophilasinaisregulated
by ERK signaling [41], the Siah may also be regulated by
ERK activation, which is increased in the diabetic retina.
ERK activation and the resulting reduction of synaptophysin
in the diabetic retina is also inhibited by an antioxidant,
lutein [36], which indicates that angiotensin II signaling
and oxidative stress may share a role in the pathogenesis of
diabetic retinopathy.
3.3. Inﬂuence of Synaptophysin Depletion. Not only that the
reduction of synaptophysin, a synaptic protein, impairs the
transmission of neuronal and visual signals, but impairment
of synaptic activity itself inhibits neuronal cell survival [34,
35]. Synaptic activity, that is, the neuronal electric stimuli,
directly increases the levels of intracellular calcium ion in
neurons, which promotes cell survival. Moreover, brain-
derived neurotrophic factor, BDNF, a neuronal survival
factor, is regulated by neuronal synaptic activity [37, 38].
Taken together, these ﬁndings suggest that the synaptophysin
levels and the related neuronal synaptic activity function
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Figure 5: Model of the molecular mechanism in diabetic retinopathy.
Angiotensin II binds to AT1R and induces ERK activation, resulting
inexcessiveUPS-mediatedsynaptophysinproteindegradation.This
impairs synaptic activity, which is critical for visual function and
neuronal cell survival.
together to inﬂuence neuronal survival and neuronal net-
work activity. The reduction of synaptophysin levels and
neuronal activity, observed 1 month after the onset of
diabetic retinopathy, is later followed by the apoptosis of
retinal ganglion cells and inner retinal cells [36]. Therefore,
one part of the neurodegenerative mechanism in the diabetic
retina is explained by the excessive degradation of a protein
that is essential for visual function (Figure 5).
4.DysregulationofUPS inPathogenesis
TheUPSisarapidandeﬀectivemethodofdegradingspeciﬁc
proteins, and in many cases a protein is degraded only in
response to a particular cellular signal or event [42]. Ubiqui-
tin molecules are attached to targeted proteins and variably
elongated. This process involves the coordinated actions
of three enzymes—a generally distributed E1 ubiquitin-
activating enzyme, several more speciﬁc E2 ubiquitin-
conjugating enzymes, and highly speciﬁc E3 ubiquitin ligases
for the targeted protein.
4.1. Excessive Degradation of Proteins Essential for Tissue
Function. The UPS involvement in pathogenesis has led to
interest in targeting proteasomes as a therapeutic approach
inseveralﬁelds.UPSisinvolvedincardiomyocytecellpatho-
genesis: oxidized and ubiquitinated proteins are observed in
rat hearts after cardiac ischemia/reperfusion injury [43, 44].
This may indicate the excessive degradation of proteins that
areneededinmusclecontraction.MusclewastingduetoUPS
activation is also reported in cases of chronic kidney disease,
diabetes, high angiotensin II levels, and sepsis, all of which6 Journal of Ophthalmology
cause inﬂammation, inhibit insulin signaling, and promote
glucocorticoid expression to induce protein degradation
[45–47].ThispathwaycanbeblockedbyoverexpressingIGF-
1, which inhibits atrogin-1, an E3-ligase acting for muscle
atrophy, through PI3K/AKT [46, 48].
In the retina, innate inﬂammation activates the IL-
6-STAT3 pathway, and diabetes activates the angiotensin
II-ERK pathway. Both pathways induce the UPS, most
likely through inducing a speciﬁc E3-ligase. Moreover, both
pathogenicconditions induceoxidative stress[27,36],which
oxidizes and unfolds proteins, after which they are easily
ubiquitinated and pushed into the UPS pathway.
4.2. Insuﬃcient Degradation of Proteins and Tissue Dysfunc-
tion. In contrast, modiﬁcation of the 20S proteasome sub-
unitsbythelipidperoxidationproduct4-hydroxy-2-nonenal
(HNE),whichoccursincardiacischemia/reperfusion,results
in the selective inactivation of 20S activity [49]. Thus,
modiﬁed and ubiquitinated proteins may accumulate to
induce cell death in some pathological conditions. The
UPS degrades numerous proteins, including apoptotic pro-
teins, and regulates multiple signaling pathways. In human-
dilated cardiomyopathy, the increased expression of the
proapoptosis regulator p53 has recently been associated with
UPS dysregulation and accumulation of polyubiquitinated
proteins [50].
4.3. Dysregulation of UPS and Tissue Dysfunction. Therefore,
the above ﬁndings show that the UPS, a selective and
bulk protein degradation system, may be modiﬁed through
multiple pathways. This system excessively degrades proteins
necessary for tissue-speciﬁc function and/or cell survival,
causing tissue pathogenesis. However, if this system is
overwhelmed and/or dysregulated, modiﬁed proteins can
accumulate and damage the cells. In inﬂammation, post-
transcriptional molecular regulation involves several path-
ways that induce tissue dysfunction.
5. PotentialTreatmentsof Diseasesthrough
UPS Regulation
Protein degradation damages tissue function, while it may
also protect tissue from pathogenic protein accumulations.
Since the UPS acts on speciﬁc proteins, regulating it may
improve the prognosis. Bortezomib, a dipeptide boronic
acid, is the ﬁrst FDA-approved proteasome inhibitor for the
treatment of multiple myeloma [51]. Bortezomib directly
induces cell-cycle arrest and apoptosis, and it targets the
tumor microenvironment. Combination chemotherapy reg-
imens using Bortezomib have been developed that pro-
vide high rates of long-lasting remissions. Interestingly, in
patients treated with Bortezomib, proteasome inhibition
improves myocardial ischemia/reperfusion injuries, prevents
postischemic ventricular tachyarrhythmias, promotes car-
diac hypertrophy regression, and reverses diabetes-induced
vascular endothelial dysfunction [52, 53]. Proteasome inhi-
bition can be also applied locally. In a balloon injury model
of the rat carotid artery, a locally administered proteasome
inhibitor, MG132 [54] or lactacystin [55], signiﬁcantly
reduces atherosclerotic changes. In addition to Bortezomib,
another proteasome inhibitor, Sorafenib has been also
approved by FDA for advanced cancer therapy, and another
candidate reagent is now under trial. In view of the potential
therapeutic beneﬁt of UPS regulation, its application to
retinal diseases deserves further study.
6. Conclusions
Inﬂammatory retinal diseases, including diabetic retinopa-
thy, induce inﬂammatory cytokines that inﬂuence protein
metabolism. UPS-mediated protein degradation is a signif-
icant source of tissue dysfunction. Excessive degradation
of tissue function essential proteins is an important factor
in retinal neuronal dysfunction. Further analyses of the
mechanisms that impair visual function may lead us to new
therapeutic approaches for retinal neuroprotection.
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